Tag Archives: EPR

EPR: Insiders vs. Shorts

By DividendChannel.com

The most recent short interest data was recently released by the NASDAQ for the 07/15/2013 settlement date, and EPR Properties (NYSE: EPR) is one of the most shorted stocks of the Russell 3000, based on 11.85 “days to cover” versus the median component at 5.53. There are a number of ways to look at short data, but one metric that we find particularly useful is the “days to cover” because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then divided by the average daily volume, to express the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed. …read more

Source: FULL ARTICLE at Forbes Markets

Cash Dividend On The Way From EPR Properties

By DividendChannel.com

Looking at the universe of stocks we cover at Dividend Channel, on 3/26/13, EPR Properties (NYSE: EPR) will trade ex-dividend, for its quarterly dividend of $0.79, payable on 4/15/13. As a percentage of EPR‘s recent stock price of $51.70, this dividend works out to approximately 1.53%, so look for shares of EPR Properties to trade 1.53% lower ? all else being equal ? when EPR shares open for trading on 3/26/13.
Click here to learn which 25 S.A.F.E. dividend stocks should be on your radar screen » or click here to find out which 9 other stocks going ex-dividend you should know about, at DividendChannel.com » …read more
Source: FULL ARTICLE at Forbes Markets

Photo-immunotherapy boosts nanoparticle delivery to tumors

(Phys.org)—One of the main reasons that nanoparticles can boost the effectiveness of an anticancer drug while decreasing its toxicity is that they are able to accumulate at cancerous sites in the body through the abnormally leaky blood vessels that surround most solid tumors. While enhanced permeability and retention (EPR) phenomenon is effective, it is inefficient and the vast majority of an injected dose of nanoparticle-entrapped drug is excreted from the body without ever reaching its intended target. Now, however, a team of investigators from the National Cancer Institute (NCI) has found a way of markedly enhancing the EPR effect and boosting nanoparticle accumulation in tumors by more than 20 fold. …read more
Source: FULL ARTICLE at Phys.org